These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20147897)

  • 1. Applying physiological and biochemical concepts to optimize biological drug development.
    Lowe PJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):492-6. PubMed ID: 20147897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality.
    Mould DR; Frame B
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):91S-100S. PubMed ID: 20881222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for modeling and simulation to design clinical investigations in children.
    Jadhav PR; Kern SE
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):121S-129S. PubMed ID: 20881225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.
    Gieschke R; Reigner BG; Steimer JL
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of biologics in dermatology.
    Lima XT; Seidler EM; Lima HC; Kimball AB
    Dermatol Ther; 2009; 22(1):2-21. PubMed ID: 19222513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of clinical trials with biologics using dose-time-response models.
    Lange MR; Schmidli H
    Stat Med; 2015 Sep; 34(22):3017-28. PubMed ID: 26059422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Basic concepts in pharmacology: important terms in pharmacodynamics and pharmacokinetics].
    Singer E
    Onkologie; 2008; 31 Suppl 2():21-4. PubMed ID: 18487864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.